These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27977511)

  • 1. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Pharmacogenet Genomics; 2017 Feb; 27(2):70-77. PubMed ID: 27977511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.
    Heredia-Galvez B; Ruiz-Cosano J; Torres-Moreno D; Español I; Morales-Lara MJ; Pérez-Ceballos E; González-Conejero R; Gutiérrez-Cívicos R; Vicente V; Pérez-Guillermo M; Conesa-Zamora P
    Ann Hematol; 2014 Feb; 93(2):243-7. PubMed ID: 23959437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.
    Rai R; Sharma KL; Sharma S; Misra S; Kumar A; Mittal B
    PLoS One; 2014; 9(2):e90264. PubMed ID: 24587306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Am J Hematol; 2016 Jun; 91(6):E305-7. PubMed ID: 26950187
    [No Abstract]   [Full Text] [Related]  

  • 5. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 6. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
    Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
    Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
    Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
    Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
    Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
    Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
    Trotman J; Fournier M; Lamy T; Seymour JF; Sonet A; Janikova A; Shpilberg O; Gyan E; Tilly H; Estell J; Forsyth C; Decaudin D; Fabiani B; Gabarre J; Salles B; Van Den Neste E; Canioni D; Garin E; Fulham M; Vander Borght T; Salles G
    J Clin Oncol; 2011 Aug; 29(23):3194-200. PubMed ID: 21747087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK; Levy R
    J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.